文献速递临床试验与 GCP流行病学与生物统计新药、器械与细胞基因治疗研发

洛那法尼治疗与Hutchinson-Gilford早老症患者死亡率的相关性

Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
PubMed 文献 · JAMA · 2018-01-01

该队列研究将接受洛那法尼单药治疗的HGPS患儿与按年龄、性别和居住洲匹配的未治疗患者进行比较。

要点

  • 洛那法尼单药治疗与HGPS患儿死亡率降低相关。
  • 首个试验组死亡1/27 vs 匹配未治疗组9/27,HR 0.12。
  • 合并队列死亡4/63 vs 匹配未治疗组17/63,HR 0.23。

核心结论

  • 在HGPS患者中,与未治疗相比,洛那法尼单药治疗在2.2年随访后与较低死亡率相关。
  • 研究解释受观察性设计限制。

研究设计与样本

  • 队列研究,比较按年龄、性别和居住洲匹配的同期未治疗患者与治疗患者,使用条件Cox比例风险回归。
  • 治疗队列来自两项单组单中心临床试验:ProLon1(n=27,已完成)和ProLon2(n=36,进行中)。
  • 未治疗患者来自独立的自然史研究(n=103)。
  • 随访截止日期为2018年1月1日。

主要发现

  • 共纳入258例来自6大洲的未治疗和治疗患者,123例(47.7%)为女性。
  • 141例(54.7%)有已知基因型,其中125例(88.7%)为经典型(LMNA c.1824C>T)。
  • 在已知死因的73例中,主要死因为心力衰竭(79.4%)。
  • 中位治疗持续时间为2.2年。

关键数值与推荐

  • 治疗患者接受口服洛那法尼150 mg/m2,每日两次。
  • 主要结局为死亡率。
  • 主要分析比较首个洛那法尼试验的治疗患者与匹配未治疗患者;次要分析比较两项试验合并队列与匹配未治疗患者。

临床怎么用

  • 对于HGPS患儿,洛那法尼单药治疗可能与降低死亡率相关。
  • 鉴于观察性设计,临床决策需结合患者具体情况并谨慎解释证据。

局限性

  • 研究为观察性设计,限制了因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal premature aging disease. There is no approved treatment. OBJECTIVE: To evaluate the association of monotherapy using the protein farnesyltransferase inhibitor lonafarnib with mortality rate in children with HGPS. DESIGN, SETTING, AND PARTICIPANTS: Cohort study comparing contemporaneous (birth date ≥1991) untreated patients with HGPS matched with treated patients by age, sex, and continent of residency using conditional Cox proportional hazards regression. Treatment cohorts included patients from 2 single-group, single-site clinical trials (ProLon1 [n = 27; completed] and ProLon2 [n = 36; ongoing]). Untreated patients originated from a separate natural history study (n = 103). The cutoff date for patient follow-up was January 1, 2018. EXPOSURE: Treated patients received oral lonafarnib (150 mg/m2) twice daily. Untreated patients received no clinical trial medications. MAIN OUTCOMES AND MEASURES: The primary outcome was mortality. The primary analysis compared treated patients from the first lonafarnib trial with matched untreated patients. A secondary analysis compared the combined cohorts from both lonafarnib trials with matched untreated patients. RESULTS: Among untreated and treated patients (n = 258) from 6 continents, 123 (47.7%) were female; 141 (54.7%) had a known genotype, of which 125 (88.7%) were classic (c.1824C>T in LMNA). When identified (n = 73), the primary cause of death was heart failure (79.4%). The median treatment duration was 2.2 years. Median age at start of follow-up was 8.4 (interquartile range [IQR], 4.8-9.5) years in the first trial cohort and 6.5 (IQR, 3.7-9.0) years in the combined cohort. There was 1 death (3.7%) among 27 patients in the first trial group and there were 9 deaths (33.3%) among 27 patients in the matched untreated group. Treatment was associated with a lower mortality rate (hazard ratio, 0.12; 95% CI, 0.01-0.93; P = .04). In the combined cohort, there were 4 deaths (6.3%) among 63 patients in the treated group and 17 deaths (27.0%) among 63 patients in the matched untreated group (hazard ratio, 0.23; 95% CI, 0.06-0.90; P = .04). CONCLUSIONS AND RELEVANCE: Among patients with HGPS, lonafarnib monotherapy, compared with no treatment, was associated with a lower mortality rate after 2.2 years of follow-up. Study interpretation is limited by its observational design.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Gordon LB, Shappell H, Massaro J, et al. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018. PMID: 29710166. doi:10.1001/jama.2018.3264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。